This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Novartis (NVS) Arm's Biosimilars Study Results Encourage
by Zacks Equity Research
Novartis (NVS) generic arm, Sandoz, reported positive data from two phase III studies evaluating biosimilars of Humira and MabThera respectively.
Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study
by Zacks Equity Research
Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.
Amgen Gets Positive CHMP Opinion to Expand Nplate's Label
by Zacks Equity Research
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Union Pacific, Bristol-Myers, Weyerhaeuser and Colgate
Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts
by Arpita Dutt
It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.
HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View
by Zacks Equity Research
HCA Healthcare's (HCA) third quarter witnesses increase in revenues and admissions. However, expenses too escalate. The company reiterates guidance provided earlier this month.
AbbVie (ABBV) Q3 Earnings Top, Revenues In Line, View Up
by Zacks Equity Research
AbbVie's (ABBV) Q3 earnings surpass estimates with revenues matching the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Data and Earnings Deluge
by Zacks Equity Research
Data and Earnings Deluge
Q3 GDP Hits 3.0%, Q3 Earnings Take Pre-Market Higher
by Mark Vickery
We get a first look at Q3 GDP: 3.0%, up from the consensus estimate of 2.7%, and a second consecutive 3-handle following Q2???s final read of 3.1%.
Gilead (GILD) Down on Weak HCV Sales Despite Q3 Earnings Beat
by Zacks Equity Research
Although Gilead Sciences (GILD) topped estimates in the third quarter, weak HCV sales has dampened investors sentiment.
AbbVie (ABBV) Q3 Earnings Surpass Estimates, Guidance Raised
by Zacks Equity Research
AbbVie's third-quarter 2017 earnings surpassed estimates with revenue in line with the same. Sales of its??? lead marketed drug Humira also increased compared to year ago figure.
Must-Watch Earnings Charts to End the Week
by Tracey Ryniec
In this busy earnings week, a few stocks stand out from the pack. Be sure to tune into these earnings reports.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises 2017 View
by Zacks Equity Research
Vertex Pharma (VRTX) third-quarter earnings increased from the year-ago period led by strong sales of CF drugs.
Bristol-Myers (BMY) Misses on Q3 Earnings, Opdivo in Focus
by Zacks Equity Research
Bristol-Myers (BMY) Q3 earnings miss estimates while revenues beat the same. Opdivo's label was expanded to two more indications.
Key Predictions for Q3 Earnings Reports of ABBV, MRK
by Zacks Equity Research
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.
Biotech Stock Roundup: Biogen Tops Q3 Earnings, Gilead's CAR T Drug Gets FDA Nod
by Arpita Dutt
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.
Biogen (BIIB) Tops Q3 Earnings & Sales, Spinraza Sales Up
by Zacks Equity Research
Biogen (BIIB) exceeds both earnings and sales estimates in the third quarter of 2017. The company's newest drug Spinraza's continual strong performance drives its revenue.
Can AbbVie (ABBV) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company toward an earnings beat in Q3.
Novartis (NVS) Q3 Earnings & Sales Top on New Drugs Strength
by Zacks Equity Research
Novartis AG (NVS) third-quarter results topped estimates driven by strong performance of Cosentyx and Entresto.
Healthcare ETFs Set to Soar as Q3 Earnings Unfold
by Sweta Killa
With earnings surprises well in the cards, healthcare ETFs are set to soar.
Is Gilead (GILD) Poised for a Beat This Earnings Season?
by Zacks Equity Research
A leader in the hepatitis C virus (HCV) space, Gilead Sciences' (GILD), is expected to beat expectations when it reports third-quarter results on Oct 26, after the market closes.
Abbvie Inks Immuno-Oncology Deal with Harpoon Therapeutics
by Zacks Equity Research
AbbVie (ABBV) and Harpoon Therapeutics announced that they inked an immuno-oncology research collaboration to generate novel T-cell engagers for the treatment of cancer.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
What's in the Cards for Novartis (NVS) This Earnings Season?
by Zacks Equity Research
Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.